[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biliary-colic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biliary-colic":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100641844","eus-guided-gallbladder-drainage-versus-conservative-management-in-patients-unfit-for-surgery-after-a-biliary-event-without-cholecystitis-drecon-study-100641844",false,"NCT07655778","EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study","Multicenter Comparative Clinical Trial: EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study: (DRainage, Endoscopic Ultrasound, CONservative)","DRECON","Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* Patients who have experienced a benign biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis) and are candidates for elective cholecystectomy\n* Patients deemed unfuit for surgery (age ≥ 80 years, ASA score ≥ 3, Charlson Comorbidity Index ≥ 5) or who voluntarily refuse surgery\n* Diagnosis of lithogenic\u002Flithiasic material in the gallbladder by imaging (biliary sludge, microlithiasis, and\u002For cholelithiasis)\n* Signed informed consent\n\nExclusion Criteria:\n\n* No signed informed consent\n* Prior cholecystectomy\n* Biliary event secondary to malignant etiology\n* Acute cholecystitis diagnosed according to Tokyo 2018 criteria\n* Moderate-to-severe ascites without prior paracentesis\n* Perforated gallbladder\n* Severe coagulopathy (INR \\> 1.5) or thrombocytopenia (platelets \\\u003C 50,000\u002FμL) not correctable\n* Any clinical condition preventing sedation\n* Patient dependent for daily activities (ECOG ≥ 4)","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cholecystectomy is considered the standard definitive treatment after an acute biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis). However, in elderly patients and\u002For those with significant comorbidities, surgery is often not feasible, leaving this population at high risk of biliary event recurrence (approximately 25-31% per year without treatment).\n\nEUS-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS) is an established endoscopic technique currently recommended for acute cholecystitis in patients unfit for surgery. It creates an internal fistula between the gallbladder and the adjacent digestive tract, allowing direct endoscopic access for stone clearance (cholecystoscopy). This approach could theoretically prevent biliary event recurrence similarly to cholecystectomy.\n\nThe DRECON study (DRainaige, Endoscopic ultrasound, CONservative) is a multicenter, randomized, comparative clinical trial evaluating whether EUS-GBD with LAMS reduces biliary recurrence at 1 year compared to conservative managment (CM) in patients unfit for surgery after a biliary event without acute cholecystitis who are candidates for elective cholecystectomy.\n\nPrimary hypothesis: EUS-GBD will reduce the risk of biliary event recurrence (biliary colic, acute pancreatitis, cholangitis, choledocholithiasis, or cholecystitis) at 1 year of follow-up compared to conservative management in patients unfit for surgery with gallbladder lithiasis.\n\nEstimated sample: 110 patients (55 per arm). Randomization 1:1 (EUS-GBD vs CM), stratified by centre and prior biliary sphincterotomy. Duration: 24 months recruitment + 12 months follow-up (total 3 years).\n\nParticipating centres: Hospital Universitari Mútua de Terrassa (coordinating centre), Hospital Universitari de Bellvitge, Hospital General de Granollers, Hospital Universitari Parc Taulí de Sabadell, Hospital Universitari de la Santa Creu i Sant Pau, Hospital Clínico Universitario de Valencia, Hospital General Universitario Dr Balmis and Complexo Hospitalario Universitario de A Coruña.",[27,28,29,30,31,32,33,34],"Cholecystectomy","Gallbladder","Endoscopic Ultrasound (EUS)","Cholelithiasis","Acute Pancreatitis Due to Common Bile Duct Calculus","Biliary Colic","Acute Pancreatitis Due to Gallstones","Cholangitis; Choledocholithiasis",[36,37,38,39,40,29],"gallbladder","gallblader drainage","conservative treatment","biliary recurrence","cholecystectomy","NOT_YET_RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-22","ACTUAL",{"date":47,"type":21},"2026-07-01",{"date":49,"type":21},"2029-07-01",{"name":51,"class":52},"Hospital Mutua de Terrassa","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100610049","one-vs-two-stents-for-gallbladder-disease-100610049","NCT07222527","One vs. Two Stents for Gallbladder Disease","A Randomized Trial of One vs. Two Transpapillary Cystic Duct Stents to Prevent Recurrent Symptomatic Gallbladder Disease in Non-Cholecystectomy Candidates","Inclusion Criteria:\n\n1. Males or non-pregnant females presenting with cholecystitis, biliary colic or gallstone pancreatitis.\n2. Age 18-95.\n3. Participants must be willing and able to provide informed consent\n4. Referred for ERCP for management of 1) suspected choledocholithiasis 2) acute biliary pancreatitis and\u002For 3) acute cholangitis in whom cholecystectomy is expected to be delayed \\> 30 days or are deemed to not be surgical candidates for cholecystectomy.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. History of surgically altered upper gastrointestinal anatomy (e.g. Roux-en-Y gastric bypass, Billroth I\u002FII) precluding standard ERCP\n3. History of primary sclerosing cholangitis\n4. History of gallbladder cancer\n5. History of cholecystectomy\n6. Unsuccessful biliary cannulation during ERCP -","95 Years",{"count":62,"type":21},30,[24],"This randomized trial will look at whether placing two cystic duct stents is more effective than one cystic duct stent in preventing recurrent gallbladder disease (cholecystitis, gallstone pancreatitis, or biliary colic) among patients who are not immediate surgical candidates for removal of their gallbladder.\n\nThe study will evaluate the safety profile, including rates of recurrent cholecystitis, biliary colic, and procedure-related complications, and technical success, defined as successful placement of stents into the gallbladder.\n\nThe main questions it aims to answer are:\n\n1. Does placement of two transpapillary cystic duct stents reduce the risk of recurrent symptomatic gallbladder disease compared to one stent?\n2. Is there a difference in procedure-related adverse events (post-ERCP pancreatitis, cholangitis, stent migration) between the two strategies?\n\nResearchers will compare outcomes between patients randomized to one stent versus two stents to determine which approach provides better long-term gallbladder drainage and fewer recurrent events.\n\nParticipants will:\n\nBe evaluated for eligibility and provide informed consent prior to undergoing an endoscopic retrograde cholangiopancreatography (ERCP), an endoscopy where a guidewire is placed into the bile duct from the small intestine.\n\nThey will then undergo ERCP with transpapillary cystic duct stent placement, randomized to one or two stents.\n\nAll participants will receive standard post-procedure care and follow-up assessments for recurrence, adverse events, and need for reintervention.",[66,67,68,32],"Recurrent Cholecystitis","Cholecystitis","Symptomatic Gallbladder Disease",[70,71,72,73,74,75,76,77,78,79],"gallbladder disease","symptomatic gallbladder disease","Recurrent cholecystitis","biliary colic","cystic duct stent","transpapillary gallbladder stents","high surgical risk patient","nonsurgical management gallbladder disease","gallbladder decompression","acute cholecystitis in non-cholecystectomy candidate","RECRUITING","2025-12-12",{"date":83,"type":45},"2025-12-16",{"date":81,"type":45},{"date":86,"type":21},"2028-05-27",{"name":88,"class":52},"Mayo Clinic",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100607907","study-on-the-immediate-analgesic-effect-of-yanglingquan-acupoint-treatment-for-biliary-colic-100607907","NCT07194655","Study on the Immediate Analgesic Effect of Yanglingquan Acupoint Treatment for Biliary Colic","Inclusion Criteria:\n\n* Meets diagnostic criteria for cholecystitis according to both Chinese and Western medicine;\n* Patients exhibiting clinical manifestations of biliary colic with a Visual Analogue Scale (VAS) score \\>4;\n* Aged 18 to 65 years;\n* Patients provide informed consent and voluntarily participate in this study.\n\nExclusion Criteria:\n\n* Patients meeting criteria for emergency surgery;\n* Patients with psychiatric issues unable to cooperate with treatment;\n* Patients with severe complications such as suppurative cholecystitis, suppurative cholangitis, acute pancreatitis, gallbladder perforation, tumors, or severe infections;\n* Patients with other serious comorbidities including liver, brain, kidney, or cardiovascular diseases;\n* Patients with severe local lesions (e.g., infections, burns, scalds) where acupuncture is contraindicated;\n* Pregnant women and lactating women;\n* Patients who have already undergone other treatment modalities.","65 Years",{"count":98,"type":21},248,[24],"Guided by traditional meridian and acupoint theory, conducting standardized, large-sample, multicenter randomized controlled trials (RCTs) to evaluate the clinical efficacy of pattern differentiation and meridian-based acupoint selection for biliary colic across multiple levels can provide high-quality research evidence for developing evidence-based guidelines or optimal treatment protocols. This holds significant importance for enhancing the clinical efficacy of acupuncture in treating biliary colic and promoting its widespread clinical application. Therefore, this study will conduct a multicenter, large-sample randomized controlled trial comparing the clinical effects of acupuncture at Yanglingquan (GB34) versus drug therapy for acute cholecystitis biliary colic. It aims to investigate the clinical efficacy and safety of acupuncture treatment for acute cholecystitis biliary colic.",[32],[103],"Biliary colic","2025-09-24",{"date":106,"type":45},"2025-09-26",{"date":108,"type":21},"2025-10",{"date":110,"type":21},"2026-10",{"name":112,"class":52},"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine"]